Arvinas (ARVN) reported $263M in revenue for fiscal 2025, −0.3% year on year. That ranks #2553 by revenue among 2853 SEC filers and #262 in Healthcare. It posted a net loss of −$81.0M for the same year. Revenue has grown 55.8% a year on average since 2017 ($7.6M then). The fiscal 2025 balance sheet shows $718M in total assets, $143M in cash and $400,000 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $263M | −0.3% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$119M | +$132M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$81.0M | +$118M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$274M | −$14.5M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.9M | +5.6% | FY20252025-12-31 |
| Total assetsAssets | $718M | −34.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $434M | −22.8% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $143M | +42.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $400,000 | −33.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $15.6M | −$57.6M | Open → |
| Q2 20262026-06-30 | $250M | $169M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Arvinas, Inc.
- Ticker
- ARVN
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001655759
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ligand PharmaceuticalsLGND | $268M | $124M |
| Iovance BiotherapeuticsIOVA | $264M | −$391M |
| Jushi HoldingsJUSH | $263M | −$68.6M |
| ArvinasARVN | $263M | −$81.0M |
| Omada HealthOMDA | $260M | −$12.8M |
| SchrodingerSDGR | $256M | −$103M |
| Lemaitre VascularLMAT | $250M | $57.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Arvinas — Key figures |url=https://companiesranked.com/en/company/arvinas |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Arvinas — Key figures. CompaniesRanked. https://companiesranked.com/en/company/arvinasBibTeX
@misc{companiesranked-en-company-arvinas-2026,
author = {{CompaniesRanked}},
title = {{Arvinas — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/arvinas}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-011226 · February 24, 2026
{{cite web |title=Arvinas — Key figures — 10-K (0001628280-26-011226) |url=https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/arvn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.